业界动态监管公开信息 · FDA

FDA批准首款用于治疗成人原发性膜性肾病的药物

FDA Drugs · 2026-11-14 06:33

正文 · 中文译文

FDA批准首款治疗成人原发性膜性肾病的药物 人类药物新闻与事件 会议、大会与研讨会 重要批准 CDER对话 我们的观点 CDER科学聚焦 关于……你需要了解的事项 行动 美国食品药品监督管理局已批准Gazyva(奥妥珠单抗)注射液,用于治疗有疾病进展风险的原发性膜性肾病成人患者,以诱导蛋白尿(尿中蛋白)缓解。这是首款专门获批用于治疗成人原发性膜性肾病的药物。 Gazyva此前已获批用于治疗某些癌症、活动性狼疮性肾炎和儿童期起病的特发性肾病综合征。 疾病 原发性膜性肾病是一种罕见肾脏疾病,由免疫系统攻击肾小球所致,肾小球是肾脏中清除血液废物的微小过滤器。肾小球发生炎症和损伤,将大量蛋白漏入尿中。患者可出现高胆固醇、高血压、严重肿胀、疲劳、肾衰竭及其他并发症。 支持Gazyva的数据 Gazyva的有效性和安全性在MAJESTY(NCT04629248)研究中进行了评估,该研究是一项3期、随机、对照、开放标签、多中心研究,纳入142名原发性膜性肾病成人患者。在为期104周的主要研究期间,患者被随机分配接受Gazyva或他克莫司治疗,他克莫司是另一种有时被超说明书用于原发性膜性肾病的治疗药物。 主要终点是第104周时达到蛋白尿完全缓解的患者比例,定义为尿蛋白-肌酐比值(UPCR)不超过0.3 g/g且估计肾小球滤过率(eGFR)稳定,未接受挽救治疗、未治疗失败或未提前终止研究。第104周达到完全缓解的患者比例在Gazyva组(36%)显著高于他克莫司组(6%)。 安全性信息 Gazyva的标签带有黑框警告,提示乙型肝炎病毒再激活和进行性多灶性白质脑病(PML),后者是一种由病毒引起的罕见且严重的脑部感染,发生于免疫系统减弱的人群中。在原发性膜性肾病临床研究中观察到的Gazyva最常见副作用为输注相关反应和上呼吸道感染。完整安全性详情请参阅完整处方信息。 认定 Gazyva针对该获批适应症获得了突破性疗法、孤儿药和优先审评认定。 内容截至日期: 2026年11月13日 监管产品类别 药品

正文 · 英文原文

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy News & Events for Human Drugs Meetings, Conferences, & Workshops Notable Approvals CDER Conversations From Our Perspective Spotlight on CDER Science Things to Know About... Action The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy. Gazyva was previously approved for treating certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome. Condition Primary membranous nephropathy is a rare kidney disease caused by immune system attack on the glomeruli, which are the tiny filters in the kidneys that clean waste products from the blood. The glomeruli become inflamed and damaged, leaking large amounts of protein into the urine. Patients can develop high cholesterol, high blood pressure, severe swelling, fatigue, kidney failure, and other complications. Data Supporting Gazyva The efficacy and safety of Gazyva were evaluated in MAJESTY (NCT04629248), a Phase 3, randomized, controlled, open-label, multicenter study in 142 adults with primary membranous nephropathy. During the main study period of 104 weeks, patients were randomly assigned to receive either Gazyva or tacrolimus, another treatment sometimes used off-label for primary membranous nephropathy. The primary endpoint was the proportion of patients who achieved complete remission of proteinuria, defined as a urine protein-creatinine ratio (UPCR) of no more than 0.3 g/g with a stable estimated glomerular filtration rate (eGFR) at week 104, without receipt of rescue therapy, treatment failure, or early study discontinuation. The proportion of patients achieving complete remission at week 104 was significantly higher in the Gazyva group (36%) compared to the tacrolimus group (6%). Safety Information Gazyva's label carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection caused by a virus in people with a weakened immune system. The most common side effects of Gazyva seen in the primary membranous nephropathy clinical study were infusion-related reactions and upper respiratory tract infection. See the full prescribing information for complete safety details. Designation Gazyva received Breakthrough Therapy, Orphan Drug, and Priority Review designations for this approval. Content current as of: 11/13/2026 Regulated Product(s) Drugs

English
FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界